Document is current
Any future updates will be listed below
-
Authors
Mayer, Christina Lourdes
Koeck, Kathleen
Hottmann, Margot
Redfern, Andrew
Davis, Mark
Barth, Aline
Geng, Xin
Hoppe, Carolyn
Yue, Patrick
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 14 April 2023
Accepted: 22 May 2023
First Online: 12 July 2023
Declarations
:
: This study was conducted in full compliance with the protocol, the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice guidelines, Therapeutic Goods Administration regulations, and all other applicable local laws and regulations. The study protocol and any amendments to the protocol were reviewed and approved by the clinical facility’s Human Research Ethics Committee.
: Christina Lourdes Mayer: employee: Semivida Research, LLC; paid consultant: Pfizer Inc. Kathleen Koeck: employee: Certara USA, Inc.; paid consultant: Pfizer Inc. Margot Hottmann: former employee: Global Blood Therapeutics, Inc. Andrew Redfern: employee: Linear Clinical Research; advisory board member: Novartis, Pfizer Inc., Roche, Eisai, AstraZeneca. Mark Davis: employee: Pfizer Inc. Aline Barth: employee: Pfizer Inc. Xin Geng: employee: Pfizer Inc. Carolyn Hoppe: employee: Pfizer Inc. Patrick Yue: former employee: Global Blood Therapeutics, Inc.
